Clinical Trials Browser

Phase 2 × Leukemia, Biphenotypic, Acute × lirilumab × Clear all

NCT02399917 2019-09-24

Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 2 Terminated

36 enrolled 14 charts

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute